Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 24,355 shares, an increase of 465.6% from the July 15th total of 4,306 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average trading volume of 9,824 shares, the short-interest ratio is presently 2.5 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Virtus LifeSci Biotech Products ETF stock. Comprehensive Financial Planning Inc. PA acquired a new position in shares of Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 6,971 shares of the company’s stock, valued at approximately $557,000. Comprehensive Financial Planning Inc. PA owned 1.27% of Virtus LifeSci Biotech Products ETF at the end of the most recent quarter.
Virtus LifeSci Biotech Products ETF Stock Performance
Shares of Virtus LifeSci Biotech Products ETF stock traded up $0.57 during trading on Wednesday, reaching $102.20. The company’s stock had a trading volume of 2,264 shares, compared to its average volume of 8,241. The company has a 50-day moving average price of $94.73 and a two-hundred day moving average price of $87.85. Virtus LifeSci Biotech Products ETF has a fifty-two week low of $65.68 and a fifty-two week high of $105.21.
About Virtus LifeSci Biotech Products ETF
The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus.
Featured Stories
- Five stocks we like better than Virtus LifeSci Biotech Products ETF
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
Receive News & Ratings for Virtus LifeSci Biotech Products ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virtus LifeSci Biotech Products ETF and related companies with MarketBeat.com's FREE daily email newsletter.
